Business Description
Fagron SA
ISIN : BE0003874915
Compare
Compare
Traded in other countries / regions
FAGR.Belgium0HNZ.UK4A5.GermanyFAGR.NetherlandsARSUF.USA IPO Date
2007-10-05Description
Fagron SA is a pharmaceutical compounding company operating in Belgium. It acts as a supplier of pharmaceutical care to hospitals, pharmacies, clinics, and patients across the world. The company also produces pharmaceutical raw materials, equipment, and supplies that are needed to prepare medication in the pharmacy. Its segments are namely Fagron Europe, Middle East and Africa (EMEA), Fagron North America, and Fagron Latin America. The majority of its revenue comes from Fagron North America.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.37 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.79 | |||||
Debt-to-EBITDA | 2.69 | |||||
Interest Coverage | 7.44 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.04 | |||||
Beneish M-Score | -2.72 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.8 | |||||
3-Year EBITDA Growth Rate | 5.9 | |||||
3-Year EPS without NRI Growth Rate | 7.1 | |||||
3-Year FCF Growth Rate | 4.6 | |||||
3-Year Book Growth Rate | 22 | |||||
Future 3-5Y Total Revenue Growth Rate | 7.58 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 44.41 | |||||
9-Day RSI | 44.76 | |||||
14-Day RSI | 45.2 | |||||
6-1 Month Momentum % | 13.31 | |||||
12-1 Month Momentum % | 22.05 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.92 | |||||
Quick Ratio | 1.27 | |||||
Cash Ratio | 0.78 | |||||
Days Inventory | 98.78 | |||||
Days Sales Outstanding | 31.85 | |||||
Days Payable | 91.06 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.68 | |||||
Dividend Payout Ratio | 0.26 | |||||
3-Year Dividend Growth Rate | 46.2 | |||||
Forward Dividend Yield % | 1.68 | |||||
5-Year Yield-on-Cost % | 4.52 | |||||
3-Year Average Share Buyback Ratio | -0.3 | |||||
Shareholder Yield % | 3.99 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 43.59 | |||||
Operating Margin % | 14.77 | |||||
Net Margin % | 9.25 | |||||
FCF Margin % | 11.29 | |||||
ROE % | 16.22 | |||||
ROA % | 7.05 | |||||
ROIC % | 13.32 | |||||
ROC (Joel Greenblatt) % | 62.11 | |||||
ROCE % | 12.17 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 18.39 | |||||
Forward PE Ratio | 15.92 | |||||
PE Ratio without NRI | 18.39 | |||||
Price-to-Owner-Earnings | 16.08 | |||||
PEG Ratio | 2.11 | |||||
PS Ratio | 1.7 | |||||
PB Ratio | 2.81 | |||||
Price-to-Free-Cash-Flow | 15.12 | |||||
Price-to-Operating-Cash-Flow | 10.45 | |||||
EV-to-EBIT | 15.38 | |||||
EV-to-Forward-EBIT | 12.04 | |||||
EV-to-EBITDA | 11.22 | |||||
EV-to-Forward-EBITDA | 8.96 | |||||
EV-to-Revenue | 2 | |||||
EV-to-Forward-Revenue | 1.8 | |||||
EV-to-FCF | 18.1 | |||||
Price-to-Projected-FCF | 1.03 | |||||
Price-to-Median-PS-Value | 0.78 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.94 | |||||
Earnings Yield (Greenblatt) % | 6.51 | |||||
FCF Yield % | 6.62 | |||||
Forward Rate of Return (Yacktman) % | 13.99 |